Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2002

View Archived Issues

Orally bioavailable cathepsin inhibitors designed at Naeja

New growth hormone secretagogues claimed by Lilly

Vasopressin/oxytocin antagonists and their use in preterm labor, etc.

AstraZeneca presents novel antiarrhythmic agents

Schering describes histamine H3 antagonists for use in allergic rhinitis

Cytokine production inhibitors designed by Ortho-McNeil

Novel proton pump inhibitor prodrugs prepared and tested at Takeda

MacroGenics acquires Eliance, forms alliance with UT Southwestern

Abgenix and U3 Pharma collaborate to develop therapeutic antibodies for cancer

Phase II results announced for Ciprofloxacin GR

New antiepileptic agent with excellent safety profile identified at AWD

Novo Nordisk presents structurally novel DPP-IV inhibitor

New class of DNA-targeting antifungal agents in development at Genelabs

Approaches to design of clinically useful 5-HT6 antagonists discussed by GSK

AstraZeneca introduces new breast cancer therapy in first market

RWJ-67657 inhibits proinflammatory mediators in stimulated rheumatoid synovial fibroblasts

SMP-114 exerts beneficial effects on both inflammation and bone destruction in arthritis model

Phase IIb trial demonstrates clinical activity and good safety for CTLA4Ig in RA

Good safety profile reported for TZT-1027 in clinical trial in NSCLC

Imidacrine prevents cytokinesis and induces cell death after G2 arrest

Potential use of IP6 as a novel anticancer drug with antiangiogenic and cytotoxic properties

NicVAX enters phase I testing

Product R cleared for Israeli phase I study in leukemia and lymphoma

G17DT plus chemotherapy gives encouraging results in metastatic stomach cancer

Cipralex now available for prescription in three European markets

Complete response letter issued for Amevive in psoriasis

Vertex advances VX-702 into phase I

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026